News
Article
Author(s):
In case you missed it, this week we had news about adverse event profiles among pediatric patients treated with JAK inhibitors, positive results from a phase 3 trial of dupilumab for chronic spontaneous urticaria, and the impact of tropical weather on patients with atopic dermatitis.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
The oral TYK2 inhibitor demonstrated biologic-level efficacy.
Dermatology Times spoke with Leah Howard, JD, of the NPF, and Trisha, the mother of a young girl with psoriasis, to discuss Otezla's implications in the therapeutic landscape.
Reflecting on the past 2 decades of healthcare as MJH Life Sciences® wraps up its 25-year anniversary celebration.
A recent review found the LDI shows significant symptom improvement, but needs further study for long-term maintenance.
The study reported that UST leads in dose escalation frequency, but also had lower discontinuation rates when compared to ADA and ETN.
It is important that dermatology providers can easily recognize and treat communicable sports dermatoses, writes Shanna Miranti, MMS, PA-C.
Researchers reported that second-year students were more likely to identify dermatological conditions, particularly in White patients.
A recent review found glycyrrhizin improves minoxidil's efficacy in treating AA, showing reduced severity and improved hair density.
Researchers stated the lack of reported clinical validation data raises concerns about their effectiveness and safety.
The review assessed infections, gastrointestinal AEs, blood and lymphatic disorders, and nervous system and musculoskeletal/connective tissue disorders.
Swiss researchers found significant gender differences in melanoma care, including variations in information preferences and treatment decision-making.
These positive data will support US regulatory submission by end of 2024.
New study results show promise in dupilumab for bullous pemphigoid, with 59% of patients avoiding disease relapse.
Ahead of the next 3 months of the year, Dermatology Times wants to know what conferences and meetings you plan to attend between October and December. Share your thoughts with us by September 25.
Shanna Miranti, MMS, PA-C, reviews 2 patient cases of pseudo acne fulminans, offering perspectives on treatment and management strategies.
A recent reviewed showed that self-stigma in patients with skin disease is influenced by body image issues and social support.
The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.
Hurricane flooding results in a surge of mold, mildew, and allergens, which can trigger or exacerbate AD symptoms.
The subsequent MAD portion of the study has commenced dosing. Results are anticipated in Q4.
Researchers reported several factors and indicators that may predict early-stage systemic sclerosis among patients in Japan.
Precision measurements are necessary to improve the current therapeutic armamentarium in pigmentary disorders.
Researchers authored a manuscript detailing considerations for GPP diagnosis, definitions, and management.
Misleading marketing and incomplete scientific data have led to widespread misinformation about botulinum toxin products.
Armstrong shared insights on the recently released NPF psoriasis health indicator report including pearls on national health data and unmet needs in public health campaigns.